Bio-Rad Laboratories (BIO-B) Non-Current Debt (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Non-Current Debt data on file, last reported at $802.9 million in Q1 2026.

• Quarterly Non-Current Debt fell 33.13% year-over-year to $802.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $802.9 million (down 33.13% YoY) and the FY2025 annual result came in at $1.2 billion, changed 0.11% from the prior year.
• Non-Current Debt slipped to $802.9 million in Q1 2026 per BIO-B's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Non-Current Debt topped out at $1.2 billion in Q4 2025 and bottomed at $802.9 million in Q1 2026.
• The 5-year median for Non-Current Debt is $1.2 billion (2023), against an average of $1.2 billion.
• The widest annual swing landed in 2022, when Non-Current Debt surged 11291.63%; it then slumped 33.13% in 2026.
• Tracing BIO-B's Non-Current Debt over 5 years: stood at $1.2 billion in 2022, then grew by 0.12% to $1.2 billion in 2023, then gained by 0.11% to $1.2 billion in 2024, then gained by 0.11% to $1.2 billion in 2025, then sank by 33.19% to $802.9 million in 2026.
• Per Business Quant, the three latest BIO-B Non-Current Debt figures stand at $802.9 million (Q1 2026), $1.2 billion (Q4 2025), and $1.2 billion (Q3 2025).

Peer Comparison